This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Delving into the recent topline data from the FIBRONEER-IPF clinical trial of nerandomilast in patients with IPF
Ticker(s): BOEHRINGER INGELHEIMWho's the expert?
- Treat ailments of the lungs and respiratory system, such as asthma, pneumonia, tuberculosis, complicated chest infections and chronic obstructive pulmonary diseases including emphysema.
- D.O. Pulmonologist in Rochester, NY and has over 18 years of experience in the medical field.
- Has extensive experience in Obstructive Lung Disease and Sleep Apnea.
Interview Goalto discuss the current treatment landscape and the potential of nerandomilast a therapy being developed by Boehringer Ingelheim for the treatment of interstitial lung diseases.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
